NL-OMON46787已完成3 期
BioXmark liquid fiducial markers for image guided radiotherapy in bladder cancer, a safety and performance trial - BioXmark, bladder safety and performance trial
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Patients with histologically proven primary bladder cancer
- •* Referred for bladder conserving (chemo-)radiotherapy in the AMC
排除标准
- •* Any contraindication for an cystoscopic procedure
- •* Pregnant women
- •* Age < 18 years
研究者
相似试验
招募中
不适用
BioXmark, bladder safety and performance trialMuscle invasive bladder cancerNL-OMON23138Amsterdam UMC location AMC20
已完成
不适用
BioXmark, Rectal Feasibility TrialRectal CancerNCT03265418Maastricht Radiation Oncology20
已完成
不适用
BioXmark liquid fiducial to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial10017990rectal tumorNL-OMON47645MAASTRO clinic20
进行中（未招募）
1 期
AN ASSESSMENT OF IMAGING AND CIRCULATING BIOMARKERS IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED WITH THE ANTI-VEGF MONOCLONAL ANTIBODY BEVACIZUMAB - TRAVASTIN-1. Protocol version 4.0 (20.05.2011)Metastatic colorectal cancerMedDRA version: 14.0 Level: PT Classification code 10056417 Term: Monoclonal antibody unconjugated therapy System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-011377-33-GBThe Christie NHS Foundation Trust70
尚未招募
不适用
Bi-directional translation of image based biomarkers between clinical and general populatioo specific disease problem. Improvement of Image-based biomarkers for radiological examinations.DRKS00029308niversitätsklinikum Freiburg50,000